> Hana Biosciences says it plans to submit a marketing proposal for Zensana, an oral spray for nausea, in the second quarter. Report
> BusinessWeek looks at the disappointing results coming from Amgen and examines the biotech giant's brightest prospects for putting some zip back in the company's numbers. Article
> The FDA has approved a high dose of Baxter Healthcare's Advate for hemophilia. Report
> Chelsea Therapeutics and Active Biotech have inked a deal to co-develop therapies for autoimmune disease and transplant rejection. Release
> Chelsea Therapeutics has acquired the IP rights to Synergia Pharma's L-Threo DOPS. Release
> Chutes & Ladders: Serono has appointed Jacques Theurillat to head up acquisitions and in-licensing programs. The Swiss drug developer is looking to beef up its pipeline. Report
> Gendux has submitted an orphan drug application to the EMEA for the use of ADVEXIN p53 therapy in the treatment of cancer patients with Li-Fraumeni Syndrome. Release
> Eli Lilly has submitted an application to expand the use of Cymbalta. Report
> Medicis has received FDA approval for the once-daily Solodyne for moderate to severe acne. Report
> Targeted Genetics has approved a one-for-10 reverse stock split. Report
> Labopharm has signed a licensing and distribution agreement with Grunenthal GmbH for its once-daily tramadol product for Belgium. Release
And Finally… Former FDA commissioner Mark McClellan is expected to take the stand in an upcoming trial over Plan B. Report